Uncategorized
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced financial results for the second quarter of 2020 and provided a corporate update. “We continue to make important progress in advancing a number of clinical-stage programs focused on the development of reproxalap and ADX-629, ou